<DOC>
	<DOCNO>NCT00251186</DOCNO>
	<brief_summary>This Phase II clinical trial measure effectiveness combination Capecitabine cetuximab first line treatment colorectal cancer elderly patient and/or multiple comorbidities unable receive standard chemotherapy . This study open approximately 2-3 year . Approximately 36 patient enrol study . The study begin enrol The Cancer Institute New Jersey , 17 patient first group . If 4 response note , accrual continue 36 patient throughout CINJOG .</brief_summary>
	<brief_title>First-Line Capecitabine Cetuximab Metastatic Colorectal Ca Elderly Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically proven diagnosis locally extensive metastatic colorectal cancer , amenable curative therapy . No prior therapy metastatic disease . Only 5fluorouracil leucovorin chemotherapy adjuvant setting allow last treatment give 6 month prior metastatic disease development . Patients ECOG performance score 2 AND/OR Charlson comorbidity index ³ 4 . Patients must document physician medically unable tolerate oxaliplatin and/or irinotecan base chemotherapy . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) ³ 20 mm conventional technique ³10 mm spiral CT scan . Life expectancy great 3 month . Laboratory value show adequate organ function prior go onstudy : Absolute neutrophil count ( ANC ) ≥ 2.5 x 109/L Platelets ( PLT ) 100 x 109/L Hemoglobin 9g/dl ( without transfusion ) Metabolic : Calculated creatinine clearance &gt; 50 ml/min Total Bilirubin £ 1.5 x Upper limit normal ( ULN ) AST £ 3 x ULN Patient able ingest oral medication . Ability understand sign approve informed consent . Exclusion Criteria Patients uncontrolled systemic disease patient 's colorectal cancer ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) patient admit hospital within prior month . Patients stable respiratory , cardiac , hepatic renal disease may participate subject guideline eligibility criterion . Presence dementia delirium . Unable eat , dress , bathe use toilet independently . The patient must able ambulate independently unless limit arthritis musculoskeletal condition . Patients active gastritis within last 3 month prior study entry . No synchronous prior malignancy nonmelanomatous skin cancer insitu carcinoma cervix , unless disease free &gt; 3 year . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . Pregnant woman ineligible treatment involve unforeseeable risk participant embryo fetus . Women must either child bear potential negative pregnancy test within 7 day treatment . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Men woman must willing use adequate birth control measure prevent contraception . Inability unwillingness comply protocol define treatment assessment . Prior therapy specifically directly target EGFR pathway . Prior severe infusion reaction monoclonal antibody . Any concurrent chemotherapy indicate study protocol investigational agent ( ) . Patients ingest herbal supplement , botanical vitamin excess recommend daily dose must willing stop use , 1 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>